Eton Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Eton Pharmaceuticals, Inc. on February 7, 2025. The report addresses a specific corporate event regarding intellectual property rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a regulatory milestone and does not contain financial statements.
Material Changes
On February 7, 2025, the United States Patent and Trademark Office (USPTO) granted the Company U.S. Patent No. 12,214,010. This patent covers the proprietary formulation of desmopressin oral solution for the Company's ET-600 product candidate.
Outlook, Risks, and Management Commentary
- Patent Expiration: The newly granted patent is set to expire in 2044.
- Regulatory Status: The patent is expected to be listed in the FDA Orange Book upon the product's approval.
- Pipeline Status: The Company has an additional patent application related to the ET-600 product currently under review with the USPTO.
Investor Verification Checklist
- Verify the listing of U.S. Patent No. 12,214,010 in the FDA Orange Book following product approval.
- Monitor the status of the additional patent application currently under review.
- Review the attached press release (Exhibit 99.1) for further details on the ET-600 development timeline.